Stephens Reiterates Overweight Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “overweight” rating reissued by investment analysts at Stephens in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. Stephens’ target price suggests a potential upside of 259.71% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on ATNM. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th. Maxim Group lowered their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. B. Riley lowered Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $16.00 to $2.00 in a report on Wednesday, August 7th. Finally, StockNews.com cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM opened at $1.39 on Tuesday. Actinium Pharmaceuticals has a twelve month low of $1.33 and a twelve month high of $10.24. The company has a market capitalization of $43.36 million, a PE ratio of -1.00 and a beta of 0.14. The firm’s 50-day moving average is $1.77.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ATNM. Renaissance Technologies LLC bought a new stake in Actinium Pharmaceuticals in the second quarter valued at approximately $142,000. Bank of New York Mellon Corp boosted its position in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares during the period. Vanguard Group Inc. grew its holdings in Actinium Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after acquiring an additional 82,113 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Actinium Pharmaceuticals during the second quarter valued at about $92,000. Finally, Marshall Wace LLP boosted its holdings in shares of Actinium Pharmaceuticals by 67.9% during the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after purchasing an additional 103,557 shares during the period. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).